Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the nineteen analysts that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation, eleven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $37.56.

A number of research firms have weighed in on NTLA. Wells Fargo & Company reduced their price objective on shares of Intellia Therapeutics from $60.00 to $50.00 and set an "overweight" rating for the company in a research report on Friday, February 28th. Oppenheimer decreased their price target on shares of Intellia Therapeutics from $60.00 to $40.00 and set an "outperform" rating on the stock in a research note on Monday, January 13th. BMO Capital Markets cut their price objective on Intellia Therapeutics from $70.00 to $50.00 and set an "outperform" rating for the company in a research note on Friday, January 10th. Truist Financial decreased their target price on Intellia Therapeutics from $90.00 to $50.00 and set a "buy" rating on the stock in a research report on Tuesday, March 4th. Finally, Barclays dropped their price target on Intellia Therapeutics from $55.00 to $26.00 and set an "overweight" rating for the company in a research report on Friday, February 28th.

Remove Ads

Insider Buying and Selling

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of Intellia Therapeutics stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $12.18, for a total transaction of $326,509.26. Following the completion of the sale, the chief executive officer now directly owns 941,115 shares in the company, valued at $11,462,780.70. This trade represents a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last ninety days, insiders sold 29,000 shares of company stock valued at $352,551. 3.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Intellia Therapeutics

Hedge funds have recently made changes to their positions in the stock. Wellington Management Group LLP boosted its holdings in Intellia Therapeutics by 8.5% during the 4th quarter. Wellington Management Group LLP now owns 699,814 shares of the company's stock valued at $8,160,000 after acquiring an additional 55,051 shares during the period. California State Teachers Retirement System increased its holdings in Intellia Therapeutics by 4.1% in the fourth quarter. California State Teachers Retirement System now owns 90,638 shares of the company's stock valued at $1,057,000 after buying an additional 3,596 shares during the last quarter. Polar Asset Management Partners Inc. raised its stake in Intellia Therapeutics by 1,144.1% in the fourth quarter. Polar Asset Management Partners Inc. now owns 282,400 shares of the company's stock valued at $3,293,000 after buying an additional 259,700 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in Intellia Therapeutics during the 4th quarter worth about $25,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Intellia Therapeutics by 5.0% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 483,185 shares of the company's stock worth $5,634,000 after acquiring an additional 23,173 shares in the last quarter. Hedge funds and other institutional investors own 88.77% of the company's stock.

Intellia Therapeutics Trading Down 6.2 %

NTLA traded down $0.58 during trading on Friday, hitting $8.73. The company's stock had a trading volume of 3,856,082 shares, compared to its average volume of 2,115,428. The firm has a market capitalization of $903.70 million, a price-to-earnings ratio of -1.60 and a beta of 1.97. Intellia Therapeutics has a twelve month low of $8.30 and a twelve month high of $28.23. The business's fifty day simple moving average is $10.07 and its 200 day simple moving average is $14.05.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.